1. Home
  2. DNTH

DNTH

Dianthus Therapeutics Inc.

Logo Dianthus Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.

Founded: 2015 Country:
United States
United States
Employees: N/A City: CAMBRIDGE
Market Cap: 736.3M IPO Year: N/A
Target Price: $35.00 AVG Volume (30 days): 151.5K
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -8.45 EPS Growth: N/A
52 Week Low/High: $0.57 - $33.77 Next Earning Date: 05-03-2024
Revenue: $2,826,000 Revenue Growth: -55.96%
Revenue Growth (this year): -32.31% Revenue Growth (next year): 4.91%

Share on Social Networks: